查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010922

氣喘治療市場：2026-2032年全球市場預測（依產品類型、藥物類別、給藥途徑、通路和最終用戶分類）

Asthma Drugs Market by Product Type, Drug Class, Delivery Mode, Distribution Channel, End Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，氣喘治療市場價值將達到 257.5 億美元，到 2026 年將成長至 273.1 億美元，到 2032 年將達到 396.2 億美元，複合年成長率為 6.34%。

主要市場統計數據
基準年 2025 257.5億美元
預計年份：2026年 273.1億美元
預測年份 2032 396.2億美元
複合年成長率 (%) 6.34%

對當前氣喘治療格局、醫療設備創新、監管壓力和相關人員期望等影響氣喘治療策略的因素進行權威分析。

氣喘仍然是一種慢性呼吸系統疾病，持續存在的臨床和營運挑戰不斷推動製藥和醫療設備產業的創新。儘管傳統的治療模式側重於緩解症狀和預防病情加重，但精準醫療、醫療設備工程的進步以及向整合式醫療模式的穩步轉變正在重塑臨床路徑和採購重點。在此背景下，從製造商到醫療服務提供者和保險公司等相關人員都在重新思考產品系列、患者支援服務和分銷策略，以滿足不斷變化的患者期​​望、監管要求和技術發展趨勢。

醫療設備與數位技術的融合、個人化治療路徑、不斷變化的報銷重點以及供應鏈的韌性，正在重塑氣喘治療領域的競爭優勢。

氣喘治療領域正經歷著一場變革性的轉變，多種因素交織在一起，重新定義了競爭優勢和病患療效。首先，醫療設備的創新正在超越簡單的藥物輸送機制，將吸入器和霧化器轉變為整合了感測器、行動應用程式和雲端分析的數位化生態系統。這一趨勢正在改變價值提案，使其不再僅僅關注產品本身，而是透過增強藥物依從性追蹤和支持主導在每次就診時進行干預，從而提升療效和患者參與度。

對美國在 2025 年實施的關稅措施如何影響氣喘治療產業的採購成本、製造地和籌資策略進行分析性回顧。

美國將於2025年對某些商品加徵關稅的政策決定，對氣喘藥物的供應鏈、商業策略和長期投資決策產生了多方面的影響。對某些原料、成品醫療設備和零件徵收的進口關稅，增加了部分依賴全球採購的製造商的收貨成本。因此，採購團隊和契約製造加快了重新評估供應商合約、尋找近岸和國內替代方案以及談判長期供應協議的步伐，以減輕成本波動的影響。

透過綜合細分分析，揭示產品類型、藥物分類、給藥途徑、分銷管道和最終用戶特徵如何影響臨床引入和商業策略。

從產品類型、藥物類別、給藥途徑、分銷管道和終端用戶觀點進行細分分析，可以清楚揭示商業性和臨床動態。依產品類型分類，吸入器、霧化器和片劑/膠囊劑型各有不同的市場導向因素。吸入器和霧化器優先考慮設備的人體工學設計、給藥準確性和提高遵守用藥，而口服製劑則強調特定患者群體的全身耐受性和用藥便利性。因此，產品開發團隊必須將研發投入與設備易用性和病患偏好資料結合，以最大限度地提高臨床滲透率。

從區域觀點看美洲、歐洲、中東和非洲以及亞太地區的監管複雜性、支付方期望和商業性實踐。

區域趨勢正在影響美洲、歐洲、中東和非洲以及亞太地區的監管路徑、報銷框架和商業重點，為氣喘藥物領域的相關人員帶來不同的機會和挑戰。在美洲，複雜的支付方審查和採購流程促使人們更加重視真實世界療效、成本效益證據以及能夠顯著減少氣喘急性發作和住院治療的服務模式。在該地區運營的製造商正優先考慮全面的衛生經濟學數據和整合的患者支持，以滿足處方集決策者和大規模綜合醫療保健網路的需求。

老牌製藥公司、醫療設備創新者和數位領域的新參與企業如何透過產品和服務捆綁、策略聯盟和基於證據的差異化來競爭？

氣喘治療市場的競爭格局由老牌製藥巨頭、專業醫療設備創新者、契約製造組織 (CMO) 和新興數位醫療公司組成。關鍵的商業策略強調透過產品和服務組合實現差異化，將可靠的藥理作用與便捷的使用方法、用藥依從性支持以及真實世界數據 (REW) 生成相結合。投資長期病人參與解決方案和醫療設備專業人員教育的公司正在為患者轉向其他療法設置明確的障礙，尤其是在維持治療領域，因為用藥依從性和給藥技術對臨床結果有顯著影響。

為商業、製造和臨床領導者提供切實可行的策略步驟，以增強韌性、改善患者預後並推動符合支付方需求的價值提案。

產業領導者應優先採取一系列切實可行的措施，以兼顧臨床價值、業務永續營運和商業性靈活性。首先，他們應考慮供應商多元化，並將關鍵醫療設備組件的生產轉移到近岸地區，以降低關稅相關成本飆升和全球物流中斷帶來的風險。此外，還應制定情境規劃並採用靈活的合約模式，以便在需要時快速更換供應商。

採用嚴謹的混合方法研究途徑，結合相關人員訪談、監管審查、證據整合和情境分析，以確保獲得可靠且可操作的見解。

本報告的研究結合了多種定性和定量方法，以確保獲得全面而深入的見解。主要研究包括對各類利害關係人進行結構化訪談，包括呼吸科醫生、呼吸治療師、醫院採購負責人、藥屋主任、支付方以及醫療設備製造商和公司的高級商務相關人員。除訪談外，還與臨床醫生和支付方舉行了諮詢圓桌會議，以檢驗他們對治療模式和報銷優先事項的解釋。

一項權威的綜合分析強調了醫療設備創新、真實世界數據和有韌性的供應鏈對於氣喘治療的持續成功至關重要的原因。

總之，氣喘治療正處於一個轉折點，醫療設備的進步、實證醫學證據的累積、監管方面的細微差別以及供應鏈策略，都對商業性可行性和病患益處產生影響。那些透過採用連網型設備技術、投資上市後證據以及強化供應鏈來整合這些因素的機構，將更有能力滿足臨床醫生和支付方的期望，同時提高患者的依從性和治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：氣喘治療市場：依產品類型分類

  • 吸入器
  • 噴霧器
  • 片劑和藥片

第9章：氣喘治療市場：依藥物類別分類

  • 沙丁胺醇
  • BETA-激動劑
  • 支氣管擴張劑
  • 皮質類固醇
  • 白三烯調節劑

第10章：氣喘治療市場：依給藥方式分類

  • 吸入劑
  • 口服

第11章：氣喘治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：氣喘治療市場：依最終用戶分類

  • 門診手術中心
  • 居家照護設施
  • 醫院和診所

第13章：氣喘治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章氣喘治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：氣喘治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國氣喘治療市場

第17章：中國氣喘治療藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ALK-Abello A/S
  • Amphastar Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici SpA
  • Cipla Limited
  • Dr.Reddy's Laboratories Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hetero Labs Limited
  • Lallemand Inc.
  • Merck KGaA
  • Mundipharma International Limited
  • NIOX Group PLC
  • Novartis AG
  • Novo Holdings
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Sanner GmbH
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma PLC
  • Viatris, Inc.
Product Code: MRR-434CCDA05226

The Asthma Drugs Market was valued at USD 25.75 billion in 2025 and is projected to grow to USD 27.31 billion in 2026, with a CAGR of 6.34%, reaching USD 39.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 25.75 billion
Estimated Year [2026] USD 27.31 billion
Forecast Year [2032] USD 39.62 billion
CAGR (%) 6.34%

An authoritative orientation to the current therapeutic environment, device innovation, regulatory pressures, and stakeholder expectations that define asthma drug strategies

Asthma remains a chronic respiratory condition with persistent clinical and operational challenges that continue to drive innovation across pharmaceutical and device sectors. Treatment paradigms have historically centered on symptom relief and exacerbation prevention, but a steady shift toward precision therapeutics, improved device engineering, and integrated care models is reshaping clinical pathways and procurement priorities. Against this backdrop, stakeholders from manufacturers to providers and payers are reassessing product portfolios, patient support services, and distribution strategies to respond to changing patient expectations, regulatory requirements, and technological possibilities.

The contemporary landscape reflects an intersection of clinical science and systems thinking. Advances in inhaler design and connectivity are enabling adherence monitoring and remote management, while evolving clinical guidance encourages earlier intervention and stratified therapy selection. Concurrently, supply chain considerations, manufacturing specialization, and cost containment pressures are prompting reassessments of sourcing and production footprints. Taken together, these dynamics have created both disruption and opportunity for organizations that can combine clinical credibility with operational agility and data-driven decision making.

How device-digital convergence, personalized treatment pathways, evolving reimbursement priorities, and supply chain resilience are reshaping competitive advantage in asthma therapeutics

The asthma therapeutics environment is experiencing transformative inflection driven by several converging forces that are redefining competitive advantage and patient outcomes. First, device innovation has moved beyond simple delivery mechanics toward integrated digital ecosystems that pair inhalers and nebulizers with sensors, mobile applications, and cloud analytics. This trend enhances medication adherence tracking and enables provider-led interventions between visits, thereby shifting value propositions toward outcomes and engagement rather than product-only offerings.

Second, clinical personalization is gaining momentum as clinicians and payers prioritize phenotype- and biomarker-driven approaches for moderate to severe disease management. Consequently, treatment pathways are becoming more nuanced, favoring targeted agents and combination strategies for patients with distinct inflammatory profiles. Third, regulatory and reimbursement landscapes are evolving to reward real-world effectiveness and cost containment, which increases the importance of robust post-market evidence generation and payer engagement. Moreover, supply chain resilience and procurement agility have grown in importance following global disruptions, prompting manufacturers to reassess sourcing, inventory strategies, and local manufacturing options.

Finally, patient expectations and care delivery models are shifting in parallel. Telehealth adoption, decentralized care, and home-based monitoring have expanded the touchpoints for asthma management and require integrated solutions that simplify use and improve adherence. In sum, these transformative shifts favor organizations that can integrate device innovation, clinical evidence, supply chain adaptability, and stakeholder-aligned value propositions into coherent commercial strategies.

An analytical review of how the United States tariff measures enacted in 2025 have influenced sourcing costs, manufacturing footprints, and procurement strategies across asthma therapeutics

The policy decision to implement new tariffs in the United States in 2025 has had multifaceted implications for the asthma therapeutics supply chain, commercial strategies, and long-term investment choices. Import duties on select raw materials, finished devices, and components increased landed costs for certain manufacturers that rely on globalized sourcing. As a result, procurement teams and contract manufacturers accelerated efforts to re-evaluate supplier contracts, identify nearshore and domestic alternatives, and negotiate longer-term supply agreements to mitigate cost volatility.

Consequently, manufacturers with vertically integrated manufacturing or diversified supplier bases found greater stability, while those with concentrated exposure to affected import categories faced operational pressure. In response, several organizations prioritized reprioritization of capital spend toward local production lines for devices and assembly operations, even as they continued to balance unit economics against regulatory and quality compliance costs. Moreover, tariff-driven cost pressures have influenced pricing discussions with distributors and payers, encouraging stakeholders to emphasize value-added services such as adherence programs and patient support to sustain commercial positioning.

From a strategic standpoint, the tariff environment amplified the importance of agility in sourcing and product design. Firms that proactively redesigned components to use alternative materials or modular architectures saw improved resilience. Additionally, transitional measures-such as re-classifying components, leveraging free trade agreements where applicable, and increasing inventory buffers-helped some organizations absorb short-term shocks. Looking forward, the cumulative impact of these policy changes is prompting long-term reconsideration of supply chain footprint strategies, manufacturing investments, and the balance between cost optimization and continuity of care for patients reliant on inhalers, nebulizers, and oral therapies.

Integrated segmentation analysis revealing how product types, drug classes, delivery modes, distribution channels, and end-user contexts shape clinical adoption and commercial strategies

Segmentation insights reveal distinct commercial and clinical dynamics when examined through product type, drug class, delivery mode, distribution channel, and end-user lenses. When framed by product type, inhalers, nebulizers, and tablets and pills demonstrate divergent adoption drivers: inhalers and nebulizers prioritize device ergonomics, dosing accuracy, and adherence facilitation, while oral formulations emphasize systemic tolerability and convenience for particular patient cohorts. As a result, product development teams must align R&D investments with device usability and patient preference data to maximize clinical uptake.

Viewing the landscape by drug class highlights unique therapeutic and regulatory considerations. Albuterol and beta agonists primarily address acute symptom relief and immediate bronchodilation needs, whereas bronchodilators and corticosteroids form the backbone of maintenance regimens that require longitudinal adherence and safety monitoring. Leukotriene modifiers offer alternative or adjunctive pathways for specific inflammatory phenotypes and can be positioned as oral options for patients who prefer or require noninhaled therapy. Therefore, formulary positioning and clinical messaging must differentiate acute rescue therapies from maintenance approaches while accounting for safety profiles and route-specific advantages.

Delivery mode-classified broadly as inhalable or oral-shapes both clinical outcomes and patient acceptance. Inhalable therapies offer targeted pulmonary deposition and rapid onset, but they demand patient technique competency and sometimes a higher degree of training and follow-up. Oral therapies provide convenience and familiar dosing formats but may present different systemic exposure profiles and adherence challenges. Consequently, commercialization strategies should integrate patient education initiatives and device training programs for inhalable products while reinforcing adherence supports for oral regimens.

Distribution channel considerations further inform go-to-market approaches, with hospital pharmacies, online pharmacies, and retail pharmacies each serving distinct buyer behaviors and logistical constraints. Hospital pharmacies often handle acute and high-acuity cases with institutional purchasing frameworks, online pharmacies provide convenience and subscription models that support chronic therapy continuity, and retail pharmacies remain critical for point-of-care counseling and immediate access. Aligning distribution strategies with anticipated prescribing patterns and payer pathways is therefore essential for maintaining product availability and patient adherence.

Finally, end-user segmentation across ambulatory surgery centers, home care settings, and hospitals and clinics underscores varied utilization contexts and support requirements. Ambulatory surgery centers may prioritize short-acting agents for peri-procedural management, home care settings demand durable and easy-to-use devices with remote monitoring capabilities, and hospitals and clinics require high-reliability supply and comprehensive clinical support materials. Integrating these segmentation layers supports a nuanced commercial playbook that balances product design, evidence generation, and service delivery to meet the expectations of clinicians, caregivers, and patients.

A regionally differentiated perspective on regulatory complexity, payer expectations, and commercial execution across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics influence regulatory pathways, reimbursement frameworks, and commercial priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific, creating distinct opportunities and constraints for asthma therapeutics stakeholders. In the Americas, payer scrutiny and procurement sophistication drive an emphasis on real-world outcomes, cost-effectiveness evidence, and service models that demonstrably reduce exacerbations and hospital admissions. Manufacturers operating in this region are prioritizing comprehensive health economic dossiers and integrated patient support to satisfy formulary decision-makers and large integrated delivery networks.

Across Europe, Middle East & Africa, heterogeneous regulatory regimes and reimbursement environments necessitate adaptive market entry strategies. In some European countries, centralized procurement and value-based contracting play increasing roles, while in parts of the Middle East and Africa, access challenges and infrastructure variability favor robust distribution partnerships and capacity-building programs. Consequently, cross-border strategies must balance centralized evidence generation with locally tailored payer engagement and supply chain solutions.

The Asia-Pacific region presents both rapid adoption potential and complexity due to diverse healthcare systems, regulatory standards, and patient demographics. Many jurisdictions in this region are fast adopters of digital health technologies, providing fertile ground for connected inhaler solutions and remote monitoring integration. At the same time, manufacturers must navigate price sensitivity and local manufacturing expectations, which often require creative commercialization models, technology transfers, and strategic partnerships to support sustainable access and scale. Across all regions, coordinated evidence generation, regulatory foresight, and distribution planning remain central to successful market penetration and long-term product sustainability.

How incumbent pharmaceutical firms, device innovators, and digital entrants are competing through product-service bundles, strategic alliances, and evidence-driven differentiation

Competitive dynamics in the asthma therapeutics arena reflect a blend of established pharmaceutical incumbents, specialized device innovators, contract manufacturing organizations, and emerging digital health entrants. Leading commercial strategies emphasize differentiation through product-service bundles that combine reliable pharmacology with device usability, adherence supports, and real-world evidence generation. Firms that invest in longitudinal patient engagement solutions and provider education create distinct barriers to substitution, particularly for maintenance therapies where adherence and technique determine clinical outcomes.

Strategic partnerships and alliances have become common mechanisms to accelerate capability building in areas such as connected devices, cloud analytics, and specialty manufacturing. Licensing agreements and co-development arrangements allow established drug developers to integrate hardware and software expertise without sacrificing speed to market. At the same time, contract manufacturers and regional production hubs have increased their strategic importance by offering flexible capacity and regulatory-compliant assembly services that reduce time-to-shelf and improve supply chain robustness.

Product pipeline diversification is also a notable trend, with organizations pursuing incremental device improvements, combination therapies, and enhanced patient support programs as complementary levers to traditional R&D. Meanwhile, competitive differentiation increasingly rests on the ability to demonstrate measurable improvements in adherence, reduction in exacerbations, and cost-effective care pathways through robust post-market studies. Firms that can present coherent clinical and economic narratives to payers and health systems will be best positioned to secure formulary placement and long-term utilization.

Actionable strategic steps for commercial, manufacturing, and clinical leaders to build resilience, enhance patient outcomes, and drive payer-aligned value propositions

Industry leaders should prioritize a set of pragmatic actions that align clinical value with operational resilience and commercial agility. First, diversify supplier bases and consider nearshoring manufacturing for critical device components to reduce exposure to tariff-related cost spikes and global logistics disruptions. This step should be complemented by scenario planning and flexible contracting models that allow rapid supplier substitution when necessary.

Second, invest in connected-device capabilities and patient engagement platforms that demonstrably improve adherence and collect real-world outcomes. Such investments can strengthen payer conversations and create opportunities for outcomes-based contracting. Third, expand evidence-generation programs beyond classical randomized trials to include real-world studies, registries, and health economics analyses that reflect payer and provider decision criteria. These data assets will be critical when negotiating placement with large integrated delivery networks and national health systems.

Fourth, calibrate go-to-market strategies to reflect distribution channel realities and end-user needs; tailor support materials and training programs for hospital pharmacists, retail teams, and home-care providers accordingly. Fifth, pursue selective strategic partnerships to accelerate digital and manufacturing capabilities rather than attempting to build all competencies internally. Finally, engage regulators and payers early to align clinical development plans with reimbursement requirements, reducing the risk of protracted uptake barriers following product launch. Together, these actions offer a pragmatic roadmap for converting insights into durable competitive advantage.

A rigorous mixed-methods research approach combining stakeholder interviews, regulatory review, evidence synthesis, and scenario analysis to ensure credible actionable insights

The research underpinning this report combined multiple qualitative and quantitative approaches to ensure robust, triangulated insights. Primary research included structured interviews with a range of stakeholders: practicing pulmonologists, respiratory therapists, hospital procurement officers, pharmacy directors, payers, and senior commercial leaders from manufacturers and device firms. These interviews were complemented by advisory roundtables with clinicians and payers to validate interpretation of practice patterns and reimbursement priorities.

Secondary research encompassed systematic reviews of public regulatory guidance, clinical practice guidelines, product labeling, and peer-reviewed literature to construct a comprehensive evidence baseline. Trade publications, regulatory filings, and corporate disclosures aided understanding of competitive posture and pipeline dynamics. Data synthesis followed a triangulation framework in which primary insights were cross-referenced with documentary evidence to identify convergent themes and reduce bias.

Analytical methods included qualitative thematic coding for interview transcripts, scenario analysis to test supply chain and tariff impacts under alternative assumptions, and payer pathway mapping to capture regional reimbursement nuances. Where applicable, sensitivity analyses were performed to assess the behavioral implications of device adoption and evidence generation on formulary positioning. Throughout, quality assurance measures ensured consistency and traceability of findings, including independent review of methodology and source logs.

A conclusive synthesis underscoring why device innovation, real-world evidence, and resilient supply chains are essential to sustainable success in asthma therapeutics

In conclusion, the asthma therapeutics landscape is at an inflection point where device evolution, evidence generation, regulatory nuance, and supply chain strategy jointly determine commercial viability and patient impact. Organizations that integrate these dimensions-by deploying connected-device technologies, investing in post-market evidence, and fortifying supply chains-will be better equipped to meet clinician and payer expectations while improving adherence and outcomes for patients.

Moreover, the policy and economic environment, including tariff-driven cost pressures and regional access dynamics, underscores the need for agility and forward-looking operational choices. By aligning product design with distribution realities and clinical practice patterns, companies can create defensible value propositions that resonate with stakeholders across hospitals, home care settings, and pharmacies. The path forward favors firms that are proactive in forming strategic partnerships, responsive to payer evidence requirements, and disciplined in execution, thereby translating insight into sustainable value for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Asthma Drugs Market, by Product Type

  • 8.1. Inhalers
  • 8.2. Nebulizers
  • 8.3. Tablets & Pills

9. Asthma Drugs Market, by Drug Class

  • 9.1. Albuterol
  • 9.2. Beta Agonists
  • 9.3. Brochodilators
  • 9.4. Corticosteroids
  • 9.5. Leukotriene Modifiers

10. Asthma Drugs Market, by Delivery Mode

  • 10.1. Inhalable
  • 10.2. Oral

11. Asthma Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Asthma Drugs Market, by End Users

  • 12.1. Ambulatory Surgery Centers
  • 12.2. Home Care Settings
  • 12.3. Hospitals & Clinics

13. Asthma Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Asthma Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Asthma Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Asthma Drugs Market

17. China Asthma Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ALK-Abello A/S
  • 18.6. Amphastar Pharmaceuticals, Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer AG
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. CHIESI Farmaceutici S.p.A.
  • 18.11. Cipla Limited
  • 18.12. Dr.Reddy's Laboratories Ltd
  • 18.13. F. Hoffmann-La Roche Ltd.
  • 18.14. GlaxoSmithKline PLC
  • 18.15. Hetero Labs Limited
  • 18.16. Lallemand Inc.
  • 18.17. Merck KGaA
  • 18.18. Mundipharma International Limited
  • 18.19. NIOX Group PLC
  • 18.20. Novartis AG
  • 18.21. Novo Holdings
  • 18.22. OPKO Health, Inc.
  • 18.23. Pfizer Inc.
  • 18.24. Sanner GmbH
  • 18.25. Sanofi S.A.
  • 18.26. Sunovion Pharmaceuticals Inc.
  • 18.27. Teva Pharmaceutical Industries Ltd.
  • 18.28. Verona Pharma PLC
  • 18.29. Viatris, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ASTHMA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ASTHMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 111. GCC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. GCC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 129. G7 ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. G7 ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 133. G7 ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. G7 ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 135. NATO ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. NATO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NATO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)